Advertisement
UK markets close in 1 hour 53 minutes
  • FTSE 100

    7,962.22
    +30.24 (+0.38%)
     
  • FTSE 250

    19,873.60
    +62.94 (+0.32%)
     
  • AIM

    743.90
    +1.79 (+0.24%)
     
  • GBP/EUR

    1.1695
    +0.0026 (+0.23%)
     
  • GBP/USD

    1.2637
    -0.0001 (-0.01%)
     
  • Bitcoin GBP

    56,480.18
    +1,182.95 (+2.14%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,252.71
    +4.22 (+0.08%)
     
  • DOW

    39,739.72
    -20.36 (-0.05%)
     
  • CRUDE OIL

    82.36
    +1.01 (+1.24%)
     
  • GOLD FUTURES

    2,227.00
    +14.30 (+0.65%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,490.02
    +12.93 (+0.07%)
     
  • CAC 40

    8,213.65
    +8.84 (+0.11%)
     

Can Astrazeneca's high return on equity take it to the next level?

What do you think is the main role of a company’s senior management team? Long-term business strategy? Earnings growth? Or even just making sure the wheels don’t fall off?

Top analysts and investors such as Warren Buffett and Michael Mauboussin say it is capital allocation - the deployment of company time, money, ideas, and people in ways that create additional value. It is perhaps the most fundamental driver of future share price performance. If you find a company that consistently allocates its capital profitably, chances are you are onto a long-term winner.

Unfortunately, CEOs are not generally promoted based on their ability to allocate capital, even though this is what they then go on to spend time doing.

As Mauboussin writes in one of his research papers:

ADVERTISEMENT

Capital allocation is one of management’s prime responsibilities. Yet few senior executives are versed or trained in methods to allocate capital most effectively. Further, incentive programs frequently encourage behaviors that are not in the best interests of long-term shareholders.

So if you’re only looking at sales and earnings growth, there is a vital question not being considered: how is this growth being funded?

GET MORE DATA-DRIVEN INSIGHTS INTO LON:AZN »

Screening for upwardly mobile, high quality companies

That’s where ratios like return on equity (ROE) come in. ROE measures how efficiently a company uses Shareholders’ Equity to generate profits. It is calculated by dividing net income by book value of equity.

It’s no coincidence that Buffett is a fan of the measure - companies with high ROEs tend to exhibit the high-quality, moat-like business traits that he is so fond of gaining exposure to.

What we want to find are high ROE stocks whose fantastic business models are being rewarded by the market. One way to do this might be to screen for stocks with both positive one-year relative strength and upgraded current year broker forecasts. The former ensures these shares have been outperforming the market and the latter suggests outperformance can continue.

One of the stocks that currently qualifies for this simple screen is

Astrazeneca (LON:AZN). The group has:

  • A trailing twelve month return on equity of 16.7%

  • An average current year EPS forecast upgrade of 1.43% from brokers, and

  • A one-year relative strength of 21.3%

Stocks exhibiting these traits are typically a solid mix of quality and momentum. We can see this using the StockRanks: Astrazeneca has a Quality Rank of 83 and a Momentum Rank of 98.

Studies indicate that combining factors such as Value, Quality and Momentum is a more effective way of outperforming the market over longer time frames. That's why we have constructed our StockReports to give an instant impression of how well exposed Astrazeneca (LON:AZN) is to these three factors. We go into greater detail on factor investing in this video.

Stockopedia helps you to identify return-enhancing factors such as Quality, Value and Momentum by analysing thousands of data points every day. To find out more about you find investment opportunities and analyse your portfolios then take one of our two-week free trials and have a look around.